A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 218-223

  Daigo, Y ^a   Takano, A ^a   Teramoto, K ^a   Chung, S ^b   Nakamura, Y ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ANTIBODY; AURORA B KINASE; CANCER VACCINE; CARBOPLATIN; CELL DIVISION CYCLE ASSOCIATED 1 PEPTIDE; CISPLATIN; COMPLEMENTARY DNA; CORTACTIN; GEMCITABINE; HLA A ANTIGEN; KINESIN FAMILY MEMBER 20A PEPTIDE; LYMPHOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS K PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONTANIDE ISA 51; ONCOPROTEIN; PACLITAXEL; PEPTIDE VACCINE; PROTEIN MDM2; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; STRESS ACTIVATED PROTEIN KINASE; TUBERIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER TISSUE; DNA MICROARRAY; DRUG DEVELOPMENT; DRUG RESPONSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC SCREENING; GENOMICS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NORTHERN BLOTTING; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; RNA INTERFERENCE; TISSUE MICROARRAY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CELL-PENETRATING PEPTIDES; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; SMALL CELL LUNG CARCINOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880752991     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.90     Document Type: Article

References (55)

1. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA. Cancer J. Clin. 60, 277-300 (2010).
2. Naruke, T., Tsuchiya, R., Kondo, H. & Asamura, H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann. Thorac. Surg. 71, 1759-1764 (2001). (Pubitemid 32554394)
3. Schiller, J.H. et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002). (Pubitemid 34438899)
4. Johnson, D.H. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004). (Pubitemid 41095154)
5. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005). (Pubitemid 41540110)
6. Shepherd, F.A. et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005). (Pubitemid 41058344)
7. Camidge, D.R. et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
8. Daigo, Y. & Nakamura, Y. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen. Thorac. Cardiovasc. Surg. 56, 43-53 (2008). (Pubitemid 351311467)
9. Kikuchi, T. et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22, 2192-2205 (2003). (Pubitemid 36539569)
10. Kakiuchi, S., Daigo, Y., Tsunoda, T., Yano, S., Sone, S. & Nakamura, Y. Genomewide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol. Cancer Res. 1, 485-499 (2003). (Pubitemid 36577045)
11. Kakiuchi, S. et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum. Mol. Genet. 13, 3029-3043 (2004). (Pubitemid 40045258)
12. Kikuchi, T.et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int. J. Oncol. 28, 799-805 (2006).
13. Taniwaki, M. et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int. J. Oncol. 29, 567-575 (2006).
14. Suzuki, C., Daigo, Y., Kikuchi, T., Katagiri, T. & Nakamura, Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 63, 7038-7041 (2003). (Pubitemid 37413435)
15. Kato, T. et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res. 65, 5638-5646 (2005). (Pubitemid 40911164)
16. Furukawa, C. et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res. 65, 7102-7110 (2005). (Pubitemid 41161239)
17. Suzuki, C. et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 65, 11314-11325 (2005). (Pubitemid 41821688)
18. Ishikawa, N. et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci. 97, 737-745 (2006). (Pubitemid 43983786)
19. Takahashi, K. et al. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 66, 9408-9419 (2006). (Pubitemid 44623637)
20. Kato, T. et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin. Cancer Res. 13, 434-442 (2007). (Pubitemid 46225347)
21. Suzuki, C. et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol. Cancer Ther. 6, 542-551 (2007). (Pubitemid 46332456)
22. Taniwaki, M. et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin. Cancer Res. 13, 6624-6631 (2007). (Pubitemid 350206797)
23. Mano, Y. et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci. 98, 1902-1913 (2007). (Pubitemid 350002196)
24. Kato, T. et al. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 67, 8544-8553 (2007). (Pubitemid 47437429)
25. Kato, T. et al. Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin. Cancer Res. 14, 2363-2370 (2008). (Pubitemid 351551069)
26. Dunleavy, E.M. et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 137, 485-497 (2009).
27. Hirata, D. et al. Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin. Cancer Res. 15, 256-266 (2009).
28. Sato, N. et al. Activation of WD repeat and high-mobility group box DNA binding protein 1 in pulmonary and esophageal carcinogenesis. Clin. Cancer Res. 16, 226-239 (2010).
29. Aragaki, M. et al. Characterization of a cleavage stimulation factor, 3pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clin. Cancer Res. 17, 5889-5900 (2011).
30. Masuda, K. et al. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer. Clin. Cancer Res. 17, 7712-7722 (2011).
31. Fujitomo, T., Daigo, Y., Matsuda, K., Ueda, K. & Nakamura, Y. Critical function for nuclear envelope protein TMEM209 in human pulmonary carcinogenesis. Cancer Res. 72, 4110-4118 (2012).
32. Koinuma, J. et al. Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis. Cancer Sci. 103, 577-586 (2012).
33. Nguyen, M.H., Ueda, K., Nakamura, Y. & Daigo, Y. Identification of a novel oncogene, MMS22L, involved in lung and esophageal carcinogenesis. Int. J. Oncol. 41(4), 1285-1296 (2012).
34. Hayama, S. et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 66, 10339-10348 (2006). (Pubitemid 44799753)
35. Hayama, S. et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res. 67, 4113-4122 (2007). (Pubitemid 46815056)
36. Sato, N. et al. Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes. Chromosomes Cancer 49, 353-367 (2010).
37. Nguyen, M.H. et al. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res. 70, 5337-5347 (2010).
38. Ishikawa, N. et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin. Cancer Res. 10, 8363-8370 (2004). (Pubitemid 40053398)
39. Ishikawa, N. et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 65, 9176-9184 (2005). (Pubitemid 41507981)
40. Yamabuki, T. et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 67, 2517-2525 (2007). (Pubitemid 46548936)
41. Ishikawa, N. et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 67, 11601-11611 (2007).
42. Takano, A. et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 69, 6694-6703 (2009).
43. Sato, N. et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 70, 5326-5336 (2010).
44. Nishino, R. et al. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin. Cancer Res. 17, 6272-6286 (2011).
45. Suda, T., Tsunoda, T., Daigo, Y., Nakamura, Y. & Tahara, H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 98(11) , 1803-1808 (2007). (Pubitemid 47489730)
46. Mizukami, Y. et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci. 99, 1448-1454 (2008). (Pubitemid 351761737)
47. Harao, M. et al. HLA-A2-restricted CTL epitopes of a novel lung cancerassociated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int. J. Cancer 123, 2616-2625 (2008).
48. Kono, K. et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 100, 1502-1509 (2009).
49. Yokomine, K. et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int. J. Cancer 126, 2153-2163 (2010).
50. Tomita, Y. et al. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 102, 697-705 (2011).
51. Kusakabe, K. et al. Diaminopyridine-based potent and selective Mps1 kinase inhibitors binding to an unusual flipped-peptide conformation. ACS Med. Chem. Lett. 3, 560-564 (2012).
52. Hashimoto, S. et al. Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. USA 103, 7036-7041 (2006).
53. Harbour, J.W., Worley, L., Ma, D. & Cohen, M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol. 120, 1341-1346 (2002). (Pubitemid 36105439)
54. Boon, T. & Old, L.J. Cancer tumor antigens. Curr. Opin. Immunol. 9, 681-683 (1997).
55. Scanlan, M.J., Simpson, A.J. & Old, L.J. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4, 1 (2004).